文献速递肝病

慢性乙型肝炎表面抗原水平大规模特征研究:对功能性治愈药物开发的启示

Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure.
PubMed 文献 · Gut · 2025-12-05

该研究基于4287例慢性乙型肝炎患者,描述基线qHBsAg分布及纵向变化轨迹,并分析HBsAg清除预测因素。中位基线qHBsAg为630.8 IU/mL,超过40%患者qHBsAg>1000 IU/mL;中位随访6.3年,12.3%患者实现HBsAg清除,基线ALT/qHBsAg比值≥0.27独立预测清除。

要点

  • 超过40%慢性乙肝患者基线qHBsAg>1000 IU/mL, spontaneous清除率低。
  • 基线ALT/qHBsAg比值≥0.27独立预测HBsAg清除(HR 4.904)。
  • qHBsAg中位年下降仅0.10 log IU/mL,新型抗病毒药应答欠佳。

核心结论

  • 在流行区慢性乙肝患者中,超过40%基线qHBsAg>1000 IU/mL,这些患者自发HBsAg清除可能性低且对新型抗病毒药物应答欠佳。

研究设计与样本

  • 研究纳入2009至2020年间4287例有qHBsAg检测的慢性乙肝患者,62.5%为男性,平均年龄48.0岁,45.2%正在使用核苷(酸)类似物。

主要发现

  • 中位基线qHBsAg为630.8(117.1-1875.5)IU/mL。
  • 3437例(80.2%)、2516例(58.7%)和997例(23.3%)患者基线qHBsAg分别<3000、<1000和<100 IU/mL。
  • 在2018年近期有qHBsAg检测的1593例患者中,98.9%、71.1%和26.9%分别<3000、<1000和<100 IU/mL。
  • 年龄(OR 1.019-1.049)、HBeAg阳性(OR 0.264-0.349)和HBV DNA(OR 0.675-0.832)是qHBsAg<100或1000 IU/mL的独立决定因素(均p<0.05)。
  • 有连续qHBsAg检测的患者中,qHBsAg中位年下降0.10(0.02-0.27)log IU/mL;中位随访6.3(5.7-14.3)年,526例(12.3%)实现HBsAg清除。

关键数值与推荐

  • 基线ALT/qHBsAg比值≥0.27独立预测HBsAg清除(HR 4.904,p<0.001)。

临床怎么用

  • qHBsAg水平可用于筛选适合功能性治愈药物临床试验的慢性乙肝患者,基线qHBsAg>1000 IU/mL者自发清除率低且可能对新型抗病毒药应答欠佳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Quantitative hepatitis B surface antigen (qHBsAg) is an important biomarker in chronic hepatitis B (CHB). OBJECTIVE: Establish qHBsAg profiles to guide novel drug development. DESIGN: Baseline qHBsAg profiles, longitudinal qHBsAg trajectories and predictors of HBsAg seroclearance were determined in a large CHB cohort. RESULTS: This study included 4287 patients with qHBsAg measurements between 2009 and 2020 (62.5% male; mean age 48.0; 45.2% on nucleos(t)ide analogues (NUC)) with median baseline qHBsAg of 630.8 (117.1-1875.5) IU/mL. 3437 (80.2%), 2516 (58.7%) and 997 (23.3%) patients had baseline qHBsAg <3000 IU/mL, <1000 IU/mL and <100 IU/mL, respectively (69.2%, 46.9% and 22.9% in treatment-naïve; 93.4%, 73.0% and 23.6% in NUC-treated patients correspondingly). Among patients with recent qHBsAg measurements in 2018 (n=1593), 98.9%, 71.1% and 26.9% of patients had baseline qHBsAg <3000 IU/mL, <1000 IU/mL and <100 IU/mL, respectively (99.3%, 67.1% and 34.2% in treatment-naïve; 98.7%, 73.1% and 23.0% in NUC-treated patients correspondingly). Age (OR 1.019-1.049), hepatitis B e antigen positivity (OR 0.264-0.349) and HBV DNA (OR 0.675-0.832) were independent determinants of qHBsAg <100 or 1000 IU/mL, respectively (all p<0.05). Among patients with serial qHBsAg measurements, the median qHBsAg reduction was 0.10 (0.02-0.27) log IU/mL/year. After median follow-up for 6.3 (5.7-14.3) years, 526 patients (12.3%) achieved HBsAg seroclearance. Baseline alanine aminotransferase/qHBsAg ratio ≥0.27 independently predicted HBsAg seroclearance (HR 4.904, p<0.001). CONCLUSION: In an endemic population, >40% of patients with CHB have qHBsAg >1000 IU/mL. These patients are unlikely to achieve spontaneous HBsAg seroclearance, but also have suboptimal responses to novel antivirals. Our data has important implications for novel antiviral development.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Hui RW, Wu TK, Ho KC, et al. Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure. Gut. 2025. PMID: 40764062. doi:10.1136/gutjnl-2025-335219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。